Benzinga | May 12, 2021 04:19PM EDT

Acutus Medical Announces CE Mark Approval For Suite Of EP Products In Europe, Which Includes AcQCross

Acutus Medical, Inc. ("Acutus") (NASDAQ:AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced CE Mark Approval for a broad suite of EP products that includes the AcQCross(tm) family of universal transseptal crossing devices, the next generation AcQGuide(r) MAX and VUE large bore delivery sheaths and the next generation AcQMap(r) mapping catheter. These products are designed to streamline procedural workflow in all left heart procedures and further improve ease-of-use of Acutus' proprietary non-contact mapping technology, which allows electrophysiologists to quickly and accurately map the most complex atrial arrhythmias in minutes.

"Our R&D investments are translating into meaningful clinical innovations, as we build a comprehensive portfolio of therapy management solutions that make procedures safer, simpler and more effective," said Vince Burgess, President and CEO of Acutus Medical. "We remain steadfast in our commitment to improve the treatment of complex atrial arrhythmias, and the European launch of our next generation access and diagnostic technologies is another step in that direction."